Search

Search Constraints

You searched for: Author/Creator Pariente, Jeremie

Search Results

1. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies. Issue 1 (22nd February 2019)

2. Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology. (20th December 2022)

3. Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology. (20th December 2022)

4. Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. (7th December 2020)

6. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. (7th December 2020)

7. P2‐188: Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european‐ADNI study. (1st July 2015)

8. P2‐302: CSF Beta‐Amyloid‐ and APOE Ɛ4‐Related Decline in Episodic Memory Over 12 Months Measured using the Cantab in Individuals with Amnestic MCI: Results from the European ADNI Study. (1st July 2016)

9. P3‐101: CROSS‐SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E‐ADNI STUDY. (1st July 2014)

10. P3‐315: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the European‐Adni Study. (1st July 2016)